The Eighth Annual International Employment Survey - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Eighth Annual International Employment Survey


Pharmaceutical Technology



Figure 6: A steady, and almost predictable, increase in annual compensation continues to contribute to overall employment stability and security.
These initiatives are not the only government decisions affecting pharma workers. "The biggest change in how we do business is [the] Sarbanes-Oxley [Act]," says Allen Bokser, director of analytical R&D at Hollis-Eden Pharmaceuticals (San Diego, CA, http://www.hollisedin.com/), a virtual biotech company that relies entirely on contract testing and manufacturing services. In many cases, that legislation has resulted in extra documentation and extra time needed to complete routine tasks such as obtaining contracts and making purchase orders, especially when conducting business with international service providers.

Summary

The pharmaceutical industry continues to provide a stable job market. Overall, US respondents have continued to see a steady increase in their annual salaries (see Figure 6), including a 5% increase over 2004. Women in aggregate continue to earn about 20% less than their male colleagues. Although there is a 6% increase in those who foresee a job change within the next 12 months, nearly 70% of all employees agree or strongly agree their jobs are secure.

Reference

1. US Department of Labor and the US Bureau of Labor Statistics "Highlights of Women's Earnings in 2004," report 987, Sept. 2005, http://stats.bls.gov/.

Photos courtesy of Sartorius Corporation.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here